INT212593

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.10
First Reported 2007
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 7
Disease Relevance 3.01
Pain Relevance 0.07

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (IMPDH1) small molecule metabolic process (IMPDH1) oxidoreductase activity (IMPDH1)
RNA binding (IMPDH1) nucleus (IMPDH1) DNA binding (IMPDH1)
Anatomy Link Frequency
internal 2
kidney 2
lymphocytes 1
IMPDH1 (Homo sapiens)
Pain Link Frequency Relevance Heat
fibrosis 100 74.96 Quite High
Inflammation 7 12.96 Low Low
withdrawal 116 5.00 Very Low Very Low Very Low
corticosteroid 24 5.00 Very Low Very Low Very Low
alcohol 15 5.00 Very Low Very Low Very Low
abdominal pain 8 5.00 Very Low Very Low Very Low
depression 6 5.00 Very Low Very Low Very Low
imagery 6 5.00 Very Low Very Low Very Low
Tetrahydrobiopterin 4 5.00 Very Low Very Low Very Low
Bile 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Bacterial Respiratory Disease 4 99.46 Very High Very High Very High
Toxicity 51 97.72 Very High Very High Very High
Organ Transplantation 8 96.88 Very High Very High Very High
Anaemia 76 95.96 Very High Very High Very High
Hepatitis C Virus Infection 453 90.64 High High
Liver Disease 66 85.00 Quite High
Cirrhosis 75 75.48 Quite High
Fibrosis 73 74.96 Quite High
Acquired Immune Deficiency Syndrome Or Hiv Infection 342 73.16 Quite High
Chronic Hepatitis 36 72.80 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
MPA is 5-fold more potent as an inhibitor of the type II isoform of IMPDH, which is expressed in activated T and B lymphocytes, than of the type I isoform, which is expressed in most cell types.7 Due to the expression of the more susceptible form of IMPDH, MPA preferentially inhibits the de novo guanosine nucleotide synthesis in lymphocytes.
Negative_regulation (inhibitor) of IMPDH in lymphocytes
1) Confidence 0.10 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697521 Disease Relevance 0.12 Pain Relevance 0
Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection

Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), is an inhibitor of inosine monophosphate dehydrogenase (IMPDH).

Negative_regulation (inhibitor) of IMPDH in kidney
2) Confidence 0.10 Published 2009 Journal Therapeutics and Clinical Risk Management Section Title Doc Link PMC2697521 Disease Relevance 0.08 Pain Relevance 0
Mycophenolic acid (MPA) is a fermentation product of Penicillium brevicompactum and related fungi.1 It was discovered by Gosio in 1893 and was shown to have weak antibacterial activity.2 Its ability to inhibit inosine-5’-monophosphate dehydrogenase (IMPDH) was first identified in 1969.3 Initial studies with MMF in animal models of organ transplantation yielded encouraging results and led to the initiation of human trials.4,5 Sollinger et al conducted the first human trial of MMF in 1992 in kidney transplant recipients.6 Since then, MMF has been used in combination with other medications to prevent acute rejections, for rescue treatment in acute rejection episodes and as adjuvant to facilitate “sparing” of other immunosuppressive agents.


Negative_regulation (inhibit) of IMPDH in kidney associated with bacterial respiratory disease and organ transplantation
3) Confidence 0.10 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697521 Disease Relevance 0.36 Pain Relevance 0
By inhibiting IMPDH, MPA prevents formation of guanosine monophosphate (GMP).
Negative_regulation (inhibiting) of IMPDH
4) Confidence 0.09 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697521 Disease Relevance 0.20 Pain Relevance 0
Didanosine toxicity is believed to result from increased phosphorylation of the drug because of inosine monophosphate dehydrogenase (IMPDH) inhibition by RBV, leading to an increased effect on mitochondrial DNA polymerase gamma [60].
Negative_regulation (inhibition) of IMPDH associated with toxicity
5) Confidence 0.05 Published 2007 Journal Journal of Viral Hepatitis Section Body Doc Link PMC1974798 Disease Relevance 0.84 Pain Relevance 0.07
A number of newer therapeutic agents in development include cellular IMPDH or IMPDH inhibitors, viral key enzyme inhibitors (i.e. protease, helicase and polymerase inhibitors), internal ribosomal entry site inhibitors, small and expressed interfering RNAs, ribozymes and several new IFNs (i.e.
Negative_regulation (inhibitors) of IMPDH in internal
6) Confidence 0.04 Published 2007 Journal Journal of Viral Hepatitis Section Body Doc Link PMC1974798 Disease Relevance 0.70 Pain Relevance 0
A number of newer therapeutic agents in development include cellular IMPDH or IMPDH inhibitors, viral key enzyme inhibitors (i.e. protease, helicase and polymerase inhibitors), internal ribosomal entry site inhibitors, small and expressed interfering RNAs, ribozymes and several new IFNs (i.e.
Negative_regulation (inhibitors) of IMPDH in internal
7) Confidence 0.03 Published 2007 Journal Journal of Viral Hepatitis Section Body Doc Link PMC1974798 Disease Relevance 0.70 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox